Industry News & Media

The American Chemical Society recently organized a colloquium with the American Chemistry Council regarding opportunities and challenges in using advanced toxicity testing and risk assessment methods in a Modernized TSCA.  Learn more about the presentation, including slides and audio from the presenters.


Upcoming Industry-related Webinars

Each month the ACS New York Section's Chemical Marketing & Economics Group holds a luncheon and presentation.  You can join in for the presentation through a LIVE webcast, free to all current ACS members.  More information is available at the NYSCME Group website including how to register.

Join us on May 5, at 1 P.M. ET, to hear the insights of experts about the opportunities in  this exciting area. 

Federico Mennella, Managing Director & Head of Lincoln’s International Global Chemical practice. Led Chase's Chemical and Industrial M&A advisory . Worked at Peter J. Solomon, Deutsche Bank, McKinsey, Lazard, Oppenheimer and Arthur Andersen.

Renzo Merino, Analyst, Moody’s Sovereign Risk Group. Has covered the credit of the Inter-American Development Bank, Panama, Ecuador, USA, Canada, Australia, Hong Kong, South Africa, Brazil, Peru, and Venezuela. Country Risk Analyst at BMI.

George Rodriguez (moderator), strategy and innovation advisor. Served at Asahi Glass, Nagase, Pfizer and Union Carbide (Dow). Expertise in strategy, sales and marketing, and M&A in chemicals, biopharma, biofuels, bioplastics and Latin American operations.

James S. Rosenstein, Executive Director,Brazilian-American Chamber of Commerce. Served at ViS Research, Bentley Motors, Toyota, the European Bank for Reconstruction and Dev. and BNP. Fellow at Harvard University’s Advanced Leadership Initiative.

Michael King, PhD, is Michael King Jr is a Managing Director and senior research analyst covering the biotechnology industry. Prior to joining JMP, Mr King Jr was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology.

Nathan Tinker PhD, has been Executive Director of New York BIO since 2007. He has more than 20 years of experience in working with both global and emerging technology companies.  Prior to joining NYBIO, he served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as the Director of the Nanotechnology and Biotechnology Practice at Antenna Group.  Dr. Tinker was Co-Founder and Executive Vice President of the NanoBusiness Alliance. 

Paul Pospisil, PhD, is a Senior Client Partner, Global Life Sciences at Korn Ferry. He recruits chief executive officer, chief business officer, head of research and development and other key executives. Was a co-founder of Aduro Capital LLC. He has worked at Atlas Venture, Millennium Pharmaceuticals and Altus Biologics.

Michael King, PhD, is Michael King Jr is a Managing Director and senior research analyst covering the biotechnology industry. Prior to joining JMP, Mr King Jr was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology.

Nathan Tinker PhD, has been Executive Director of New York BIO since 2007. He has more than 20 years of experience in working with both global and emerging technology companies.  Prior to joining NYBIO, he served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as the Director of the Nanotechnology and Biotechnology Practice at Antenna Group.  Dr. Tinker was Co-Founder and Executive Vice President of the NanoBusiness Alliance. 

Paul Pospisil, PhD, is a Senior Client Partner, Global Life Sciences at Korn Ferry. He recruits chief executive officer, chief business officer, head of research and development and other key executives. Was a co-founder of Aduro Capital LLC. He has worked at Atlas Venture, Millennium Pharmaceuticals and Altus Biologics.


Network & Learn: Consultants Tackle Your EPA Questions

Industry Member Programs, in conjunction with the ACS Webinars team, are currently preparing a video that will feature a trio of chemical industry consultants answering questions that are commonly asked about EPA regulations.

The video is now available. We invite you to begin planning a meeting around the video.    

For more information, visit the Network & Learn website.


Learn from the best and brightest minds in chemistry.

Hundreds of webinars presented by subject matter experts in the chemical enterprise. LIVE every Thursday at 2pm ET!
Join Our Mailing List!


We have a topic of interest for every chemist. Go ahead, dive into these diverse categories and discover our growing archive of past webinars. 

Upcoming Webinars

Who Will Win the #ChemNobel? Predicting the 2016 Nobel Laureate(s) in Chemistry
Wednesday, September 28, 2016 @ 2-3pm ET

Join us for our annual Nobel Prize prediction event. Tune in the week before, on Sept. 28, for a lively discussion of Nobel Prizes past and future, and cast your own virtual vote.

Mary Ann Meador
Mary Ann Meador
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,

Dealing with Reactive Drug Metabolites in Drug Discovery: Can We Predict Toxicities of Drug Candidates that form Reactive Metabolites?
Thursday, September 29, 2016 @ 2-3pm ET

Deepak Dalvie of Pfizer discusses pragmatic risk mitigation strategies for toxicity and the path forward for drug candidates that carry a RM liability.

Mary Ann Meador
Mary Ann Meador
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,

The Chemistry of Life: Treating Cancer with Nanoparticles Powered by the Sound of Light
Thursday, October 6, 2016 @ 2-3pm ET

Justin Harris discusses the development of molecularly-targeted nanoparticles to detect cancer and other similar diseased tissue. 

Mary Ann Meador
Mary Ann Meador
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,

Failure: Why Science Is So Successful
Thursday, October 13, 2016 @ 2-3:30pm ET

Stuart Firestein shares how science is an iterative process in which revision is a victory and failure is critical to its continued success. 


Cosmetic Chemistry: Novel Approaches using Natural and Renewable Ingredients
Thursday, October 20, 2016 @ 2-3pm ET

Richard Blackburn of the University of Leeds investigates the possibility of isolating actives from plant materials using green chemistry principles as well as how to find applications for these actives to produce both sustainable and functional cosmetics.

Mary Ann Meador
Mary Ann Meador
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,

Chemistry of Life: Instantly Treating Wounds with Hemostatic Gel
Thursday, November 3, 2016 @ 2-3pm ET

Join us as Joe Landolina shares progress being made with hemostatic gel that can stop the bleeding in seconds rather then traditional closures which take minutes.